Raising a Series B or later in biotech.
Later biotech rounds fund mid-stage trials and a broader pipeline. Investors want clinical data in people and a clear story for the next readout.
Biotech
Biotech investors fund data, not traction. Each round buys the next experiment that removes a risk: a preclinical result, an IND, a clinical readout. Grants and licensing deals often matter as much as equity.
What later-stage investors expect in biotech
By Series B the conversation is about clinical data and value at the next readout.
Clinical data in people
- Phase 1 safety results, ideally with early efficacy
- A Phase 2 design that can show proof of concept
- Biomarkers or endpoints that make results clear
A pipeline beyond one asset
- A second program or indication moving forward
- A platform that keeps producing candidates
- A plan for which programs to fund and which to partner
Partnering and exit options
- Interest from pharma in licensing or co-development
- Deal terms you would accept, and when
- A view on listing versus a sale after the readout
How the round comes together
Later biotech rounds bring in crossover investors alongside specialist funds.
- 1 · A specialist or crossover leads
- 2 · Insiders follow
- 3 · Strategics and families
Multi-stage VCs
Often leads
Specialist and crossover funds lead most later biotech rounds.
Corporate VCs
Sometimes
Pharma invests beside a licensing deal or option on the asset.
Family offices
Sometimes
Families with life science focus take positions after human data.
Grants & non-dilutive
Now and then
Foundations and public programs can co-fund trials in unmet areas.
Preferences and partnering terms
Later rounds bring larger checks and negotiated terms. Liquidation preferences decide who gets paid first. Licensing deals bring upfront cash and milestones but can limit future options, so model both together.
The slides investors read first
Clinical data
What the trial showed, with confidence.
Next readout
Design, timing and what success looks like.
Pipeline
Programs ranked by stage and value.
Partnering
Deals done, in talks, or held back.
The plan
Cash runway through the next readout.
Questions founders ask
What is a crossover round in biotech?
A private round led by investors who also buy public stocks. It often comes before a listing and signals that public investors may support the company.
Should I license my asset or keep raising?
It depends on how much value the next readout adds and what it costs to get there. Many companies partner one program to fund another.
Sources
Sources: FDA guidance on IND applications and clinical phases; federal research grant program guidance; university technology transfer practice; investors' published criteria. Editorial content, reviewed quarterly. Not financial, legal or medical advice.
Other stages
Related sectors
Who funds this round
Learn the terms
Run the numbers
Raise in your city
Inside Unicorn Factory
Free account
Investor matching is coming to your free account. Create it now and we will match your round the day it opens. Until then, get an honest read on your deck.